major characteristics: 1) expression/lack of well-defined surface markers; 2) adhesion to plastic; and 3) ability to undergo osteoblastic, chondrogenic, and adipocytic differentiation (3) . MSC have been established in animal models and humans after myocardial infarction (2, 9) . Despite these achievements hurdles exist. First, the number of available stem cells is sufficient to treat many animal models but is too low for clinical application. Depending on the route of administration only a minority (3-6%) enter damaged myocardium. Secondly, positive therapeutic effects cannot be clearly attributed to the regenerative power of stem cells. Rather, paracrine and trophic effects seem to be more likely (5) . Finally, MSC are not a homogeneous entity.
Numerous approaches are possible to address these issues: 1) MSC must be characterized according to a standard protocol to enable reproducibility and comparison of results among different groups and institutions (3); 2) (genetic) modification of MSC may be needed to improve homing, differentiation, or migration before in vivo application in order to improve clinical benefits; 3) attempts should focus on a clinical and preferably GMP-grade application; and 4) a practical number of MSC must be isolated and prepared for therapeutic use in humans.
In factors than controls and thus were able to contribute to cardiac regeneration and improvement in an animal model. The authors propose that these effects are mediated by activation of Toll-like receptor 3 (TLR3) on the MSC surface. TLR3 has been shown to stimulate production of many trophic factors, e.g., interleukin-6, stromal cell-derived factor-1, and/or vascular endothelial growth factor. In contrast to other reports, Mastri et al. were able to demonstrate functional benefits of their cell therapy, i.e., decrease in fibrosis and apoptosis and increase in angiogenesis in a hamster heart failure model. Thus, clinical application of such modified MSC has potential to be more effective, practical, and cheaper than current approaches. Additionally, the MSC used in this report were characterized according to an international standard (3).
Mastri et al. propose that TLR3 activation directly promotes phosphorylation of multiple MAP kinases (MAPKs). In fact, phosphorylation of these MAPKs could result from different ligands, receptors, and conditions and is not specific for TLR3. Consequently, to confirm that TLR3 directly acts via this proposed mechanism will require additional approaches, such as reversal by addition of blocking antibodies.
The authors break new ground by focusing on production of trophic factors rather than concentrating solely on the abilities and differentiation of stem cells. It would be informative if the authors could demonstrate that MSC do not need to be placed directly into the heart to display their beneficial effects, but instead that intramuscular injection is sufficient to produce such clinical effects. However, in vivo trials with MSC have reported side effects, such as, recently, ossifications or Ewing's tumors (1) . As a result of this and because most trophic factors can be produced recombinantly, an important further question for future studies will be to determine whether MSC are needed or whether trophic factors are sufficient to promote regeneration in the heart and perhaps other tissues. Overall, the approach described by Mastri et al. introduces a novel way to produce tissue regeneration that could avoid the aforementioned limitations. In their earlier work the authors demonstrated that heart failure therapy could be accomplished in a cell-free fashion by injection of MSC-conditioned medium (6) . The ability to replace fetal calf serum with human AB serum or thrombin-activated platelet-rich plasma (or perhaps with specific trophic factors) in the growth medium of MSC may open a new design for clinical trials. Thus, future efforts to promote myocardial regeneration could involve injection of trophic factors that induce beneficial effects on other cell types, e.g., CD34
ϩ hematopoietic stem cells, rather than relying on stem cells themselves (5).
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